The first clinical study investigating the use of the direct oral anticoagulant, rivaroxaban, to prevent blood clots in patients with cancer at high-risk has been published in the New England Journal of Medicine.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
